Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > 64 cents really??
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(76)
•••
Comment by brad129on Dec 09, 2020 10:21pm
128 Views
Post# 32074244

RE:RE:RE:64 cents really??

RE:RE:RE:64 cents really??

skier, that is incorrect info Q4 and year end numbers are March 31 due date 90days after the quarter. This is the quarter I always hate having to wait the extra 45days. Hopefully we get some good news regarding Aristotle by Feb the 14th.



skier59 wrote: Let's not forget that Tripp did mention that Revenues for Q4 will be, and are much higher than Q3. So mid February on Valentines Day, we all could get a really big Heart of Love with and really nice Q4 report and the Launch of Aristotle.

For some reason today Anonymous sold us down the last 30 minutes of the day. Tax Loss Season should not affect our SP this year in any negative manner.

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities